<DOC>
	<DOCNO>NCT01304303</DOCNO>
	<brief_summary>Phase I study SPARC1023 alone combination carboplatin</brief_summary>
	<brief_title>Pharmacokinetic Safety Study SPARC1023 Alone Carboplatin Combination</brief_title>
	<detailed_description>Pharmacokinetic profile dose escalation study SPARC1023 administer 30-min infusion .</detailed_description>
	<criteria>Age ≥18 year ECOG Performance Status ≤ 1 . Estimated life expectancy least 12weeks ; Measurable disease per RECIST guideline ( Version 1.1 ) ; Any malignancy within past 5years , except nonmelanoma skin cancer , cervical intraepithelial neoplasia , situ cervical cancer Known hypersensitivity study drug Treatment anticancer agent within 28 day study entry Presence clinically evident active CNS metastasis , include leptomeningeal involvement , require steroid radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>solid</keyword>
	<keyword>tumor</keyword>
	<keyword>taxane</keyword>
	<keyword>platinum</keyword>
</DOC>